| 1992 | ICI announces its intention to split off its Biochemicals division. | |||||
| 1993 | The Biochemicals division
is spun off as Zeneca which includes ICI specialty chemicals operations, renamed as Zeneca Specialties. |
|||||
| 1999 | Zeneca Specialties acquires Covion Organic Semiconductors, a maker of light-emitting polymers (LEPs) owned by Hoescht | |||||
| Zeneca merges with Astra,
forming AstraZeneca, which then sells off Zeneca Specialties in a management buyout backed by Cinven and Investcorp Under terms of the £1.3 billion ($2.1 billion) buyout agreement, the company is renamed as Avecia Avecia
began business with operations in five primary sectors: |
||||||
| In December of that year, Zeneca sold off its agrochemicals business as well, into a merger with Novartis creating Syngenta. | ||||||
| In a move to boost its Life Science Molecules (LSM) operations, Avecia acquires Boston BioSystems which had already gained a leading place as developer of oligonucleotides--also known as DNAmolecules -- complementing Avecia's own newly established DNA medicine plant, opened in Scotland in 1998 and expanded in mid-1999. | ||||||
| 2000 | acquired
Torcan Chemical Ltd., based in Ontario, Canada. Torcan Chemical Limited provides contract based laboratory testing, research, active pharmaceutical ingredient manufacturing, and trial management services. |
|||||
| boosted its Neoresins
operations, forming Image Polymers, a 50-50 joint venture
partnership with Mitsui Chemicals to develop biomodal
toner resins. 当初は ICI と三井東圧のＪＶ ＩＣＩ は後に持分を Avecia に売却した。 ◇会社名 :Image Polymers Company ◇事業内容 :ト ナー樹脂の製造・販売 ◇設立 :1988年 ◇所在地 :米 国、テネシー州 ◇社長 :Tom Kinneman ◇会社名 :Image Polymers Europe ◇事業内容 :ト ナー樹脂の製造･販売 ◇設立 :1996年 ◇所在地 : 英 国、スコットランド ◇社長 :Tom Kinneman |
||||||
| 2001 | to focus on LSMs and NeoResins | selling
Novacote packaging, adhesives, and coatings business to COIM
GROUP(Chimica
Organica Industriale Milanese), in
Italy. Novacote:specialty laminating adhesives and coatings for the flexible packaging industry. |
||||
| 2002 | sells off the Stahl leather chemicals operation to Investcorp for EUR 375 million. | |||||
| 2003 | acquires chiral technologies from Synthon Chiragenics | sells
its mining chemicals division to Cytec Industries Inc (metal extractant products and intermediates and stabilizers business) |
||||
| 2004 | sells biocides operations (primarily water treatment and pool cleaning products) to Arch | |||||
| sells the additives business to Lubrizol | ||||||
| 2005 | ----
|
sells Avecia Fine Chemicals to KemFine, the fine chemicals business created via a management buyout from chemicals group Kemira last year | ||||
| sells
OLED (organic light emitting diodes) materials and
polymer electronics businesses to Merck KGaA of Damstadt,
for Euro50 million. The sale included Avecia's displays business - Covion Organic Semiconductors GmbH in Frankfurt, Germany and its polymer electronics research and development activities based in Manchester, UK. |
||||||
| sells
NeoResins business to Royal DSM N.V (Avecia's coating resins business). DSM had paid Avecia Euro515 million in cash for the entire NeoResins business on a cash and debt free basis. |
||||||
| 2006 | sells Avecia Inkjet to Fuji Film | |||||
| sells jv Image Polymers & Image Polymers Europe to Mitsui | ||||||
| 2010 | (The group now operates two main businesses within the Biotechnology segment, Biologics and Oligo Medicines) | sells Avecia Biologics to Merck & Co. Inc., (operating in the United Kingdom as MSD) | ||||
Effective
1st Feb 2010, MSD (operating in the US and Canada as Merck &
Co,. Inc.) has completed its acquisition of Avecia Biologics
Limited, a contract manufacturing organisation with specific
expertise in microbial-derived biologics.
Under the terms of the agreement, MSD acquires Avecia Biologics
Limited and all its assets, specifically the process development
and scale-up, manufacturing, quality and business support
operations of Avecia Biologics located in
Billingham, North East England, UK.
Avecia is a privately owned biotechnology group providing contract development and manufacturing services in the fields of microbial-derived biopharmaceuticals and oligonucleotide medicines.
The group’s Biologics Business, based at Billingham in the north east of the UK has been developing processes and making protein-based biologics to cGMP since 1998. Products currently being worked on include medicines targeted at forms of cancer, heart disease and stroke.
In Milford, MA, the group’s OligoMedicines business carries out process development and manufacture of oligonucleotide therapeutics by sequential solid state synthesis to produce pharmaceuticals comprised of short strands of DNA or RNA.
---
The group now operates two main businesses within the Biotechnology segment, Biologics and Oligo Medicines, having completed the disposal of its remaining specialty chemicals business segments during 2005 and 2006. These two businesses provide contract manufacturing and development services to developing Biotech and established Pharmaceutical companies.
The Biologics business is based in Billingham in the North East of England and manufactures pharmaceutical drug substances based on recombinant proteins using microbial fermentation processes.
The Oligo Medicines business is based in Milford, Massachusetts, USA and makes oligonucleotide based drug substances using solid-phase synthesis. These drug substances are effectively short strands of DNA or RNA.